Biotech Values

[pcrutch]

RGLS

The idea this is worth ~450M (17.33 - 6.77 x 43.34M OS) more today than 2 days ago seems absurd.

- 7-day data were only ~2.5 logs when you exclude the one rapid responder. Even at day 29, most had ~3 log reduction

- Running a trial in the US will be very challenging

- FDA has recently told Santaris they would need quite long follow up data ( 5 years )

- FDA unlikely to approve a drug based on RVR data and will still require 12 weeks. I don't see any reason for them to change their minds here especially with Harvoni and ABBV regimen coming.

http://files.shareholder.com/downloads/AMDA-14LKIJ/3566165809x0x787853/66089b1b-f1db-47f2-8972-355f0cbc8ae9/RG-101%20PoC%20Presentation%2010%2022%2014.pdf